ECSP024340A - HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELL ADHESION - Google Patents
HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELL ADHESIONInfo
- Publication number
- ECSP024340A ECSP024340A ECSP024340A ECSP024340A EC SP024340 A ECSP024340 A EC SP024340A EC SP024340 A ECSP024340 A EC SP024340A EC SP024340 A ECSP024340 A EC SP024340A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies
- human
- preparation
- polynucleotides
- cell adhesion
- Prior art date
Links
- 230000021164 cell adhesion Effects 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100030385 Granzyme B Human genes 0.000 abstract 1
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 abstract 1
- 238000012151 immunohistochemical method Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Comprende una preparación de un anticuerpo humano, en la cual el anticuerpo se une a la proteína MN y un método para su preparación. Los anticuerpos monoclonales de MN humana o fragmentos de anticuerpo de MN orientados a la repetición geedlp dentro del dominio de proteoglicano. Además de unirse a la repetición peptidica, los anticuerpos anti-MN humanos pueden inhibir la adhesión celular de las células CGL-1 a las placas de plástico recubiertas con MN. Los anticuerpos anti-mn humanos se han usado para diagnosticar y cuantificar la expresión de mn en celular y tumores cancerosos con el uso de los métodos FACS e inmunohistoquimicos. Por lo tanto se describe además el uso de estos anticuerpos para la manufactura de medicamentos útiles para el tratamiento de canceres en los cuales la mn esta regulada en sentido ascendente. Se suministra, además, polinucleotidos que codifican los anticuerpos de mn humana. Estos polinucleotidos pueden usarse, por ejemplo, para producir cantidades de los anticuerpos para uso terapéutico o de diagnóstico. También se definen vectores de expresión y células huésped que comprenden dichos polinucleotidos. Por otro lado, se describe un método para detectar un antigeno de mn en una preparación de prueba.It comprises a preparation of a human antibody, in which the antibody binds to the MN protein and a method for its preparation. Monoclonal antibodies of human MN or MN antibody fragments oriented to geedlp repeat within the proteoglycan domain. In addition to binding peptide repeat, human anti-MN antibodies can inhibit cell adhesion of CGL-1 cells to plastic plates coated with MN. Human anti-mn antibodies have been used to diagnose and quantify the expression of mn in cell and cancerous tumors with the use of FACS and immunohistochemical methods. Therefore, the use of these antibodies for the manufacture of useful medicines for the treatment of cancers in which the mn is regulated upstream is also described. In addition, polynucleotides encoding human mn antibodies are supplied. These polynucleotides can be used, for example, to produce amounts of the antibodies for therapeutic or diagnostic use. Expression vectors and host cells comprising said polynucleotides are also defined. On the other hand, a method for detecting an mn antigen in a test preparation is described.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34365701P | 2001-10-18 | 2001-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP024340A true ECSP024340A (en) | 2003-05-26 |
Family
ID=38116113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP024340 ECSP024340A (en) | 2001-10-18 | 2002-11-19 | HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELL ADHESION |
Country Status (2)
| Country | Link |
|---|---|
| EC (1) | ECSP024340A (en) |
| ZA (1) | ZA200402837B (en) |
-
2002
- 2002-11-19 EC ECSP024340 patent/ECSP024340A/en unknown
-
2004
- 2004-04-15 ZA ZA200402837A patent/ZA200402837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200402837B (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036833A1 (en) | HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELLULAR ADHESION. | |
| CO2022013525A2 (en) | Antibodies against sars-cov-2 and methods of using them | |
| CY1123400T1 (en) | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES | |
| PE20050712A1 (en) | RG1 ANTIBODIES | |
| CL2021001986A1 (en) | Antibodies and chimeric antigen receptors specific for orphan receptor tyrosine kinase-like receptor 1 (ror1). | |
| BR112021024544A2 (en) | Anti-ceacam5 monoclonal antibody and method of preparation and use of same | |
| CY1118549T1 (en) | USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMISTRY FOR TREATMENT OF BREAST CANCER | |
| CR10143A (en) | ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME AND METHODS OF USE IN CANCER THERAPY | |
| ATE488530T1 (en) | INTERNALIZING ANTIBODIES SPECIFIC TO THE RAAG10 CELL SURFACE TARGET | |
| CY1119112T1 (en) | K-RAS ANTI-EGFR DIAGNOSTIC TREATMENTS AND TREATMENT | |
| PE20071055A1 (en) | ANTI MN ANTIBODIES | |
| BR0311799A (en) | Hpam4 Monoclonal Antibody | |
| CO6251370A2 (en) | A HUMANIZED CD20 UNION MOLECULA THAT INCLUDES AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE DOMAIN (VH) AND A LIGHT IMMUNOGLOBULINE CHAIN VARIABLE DOMAIN (VL) AND SAME USE METHODS | |
| MX2009009450A (en) | He4 monoclonal antibodies and methods for their use. | |
| EA201491977A1 (en) | ANTIBODY MOLECULE TO GCC AND ITS APPLICATION FOR TESTING SENSITIVITY TO GCC-TARED TREATMENT | |
| BR0116763A (en) | Human Specific Antibodies for Selective Cancer Therapy | |
| ATE526037T1 (en) | METHOD FOR KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS | |
| CY1122627T1 (en) | ANTIBODIES TO CEACAM6 AND USES THEREOF | |
| ATE412756T1 (en) | METHOD FOR DIAGNOSING CANCER USING A CHIMERIC TOXIN | |
| ES2090052T3 (en) | MONOCLONAL ANTIBODIES (MAK) AGAINST ANTIGENS ASSOCIATED WITH TUMORS, THEIR PREPARATION AND USE. | |
| BR112023018450A2 (en) | ANTI-CD47 MONOCLONAL ANTIBODY AND ITS USE | |
| CO2023009100A2 (en) | Bispecific antibodies against ceacam5 and cd47 | |
| CR20220329A (en) | Anti-mertk antibodies and methods of use thereof | |
| BR112022009611A2 (en) | ANTI-ROR-2 ANTIBODIES AND METHODS OF USE | |
| ES2173910T3 (en) | HUMANIZED ANTIBODIES DIRECTED AGAINST ANTIGEN A33. |